Partnering
Lupagen works with biopharma companies combining their transgene product or novel targets with our Side CAR-T® delivery system to develop first-in-class extracorporeal cell & gene therapies. Our proprietary delivery technology, including devices, kits and nanoparticle formulations, is available via contract development and supply agreements on a non-exclusive basis.
Lupagen's technology can simplify, enable, and improve a wide range of cell & gene therapies involving peripheral blood cells including lymphocytes, monocytes and hematopoietic stem cells including, but not limited to the following therapy types:
CAR/TCR-based cell therapies (T-Cell,
NK Cell, Macrophage)
Gene Therapy
(Gene Editing)
Targeted Drug Delivery (Immunosuppression, Autoantigens)
Other non-viral
Please feel free to contact us for more information if you are a biopharma company or academic institution looking for effective alternatives to ex vivo and in vivo cell & gene therapy delivery and need to:
-
Mitigate biodistribution and immunogenicity challenges
-
Enable redosing
-
Lower manufacturing costs and complexity
-
Broaden treatable patient population and access
-
Avoid chemotherapy preconditioning regiments
-
Shorten vein-to-vein treatment time
-
Accelerate pathway to the clinic
